Abstract
Background
Recent studies suggest that the relationship between cancer stem cells (CSCs) and the vascular niche may be bidirectional; the niche can support the growth and renewal of CSCs, and CSCs may contribute to the maintenance of the niche. There is little knowledge concerning the role of breast cancer stem cells in promoting tumor angiogenesis.
Aim
For human breast cancers, CSCs have been shown to be associated with a CD44+/CD24− phenotype. We investigated the potential activities of CD44+/CD24− breast cancer stem cells in promoting tumor angiogenesis.
Methods
The expression of pro-angiogenic genes was determined by quantitative real-time RT-PCR. Endothelial cell migration assays were employed to evaluate effects of conditioned media from CD44+/CD24− on human umbilical vein endothelial cells. A chorioallantoic membrane (CAM) assay was used to study the potential of CD44+/CD24− cells to promote angiogenesis.
Results
In our study, CD44+/CD24− cells expressed elevated levels of pro-angiogenic factors compared with CD44+/CD24+ cells. CD44+/CD24− cell-conditioned media significantly increased endothelial cell migration. Breast cancer cell lines enriched with CD44+/CD24− cells were more pro-angiogenic in the CAM assay than those lacking a CD44+/CD24− subpopulation. CD44+/CD24− cells sorted from MCF-7 cell lines were more pro-angiogenic in a CAM assay than CD44+/CD24+ cells. Furthermore, the VEGF concentration was significantly higher in CD44+/CD24− cell-conditioned media than in CD44+/CD24+ cell-conditioned media. The pro-angiogenic effect of CD44+/CD24− cells on endothelial cells was abolished by bevacizumab.
Conclusion
Our findings demonstrate that CD44+/CD24− breast cancer stem cells have substantial pro-angiogenic potential and activity. This provides new insights to explore in the development of targeted therapies.
Similar content being viewed by others
Abbreviations
- CSCs:
-
Cancer stem cells
- HUVECs:
-
Human umbilical vein endothelial cells
- FCS:
-
Fetal calf serum
- PBS:
-
Phosphate-buffered saline
- CAM:
-
Chorioallantoic membrane
References
Calabrese C, Poppleton H, Kocak M et al (2007) A perivascular niche for brain tumor stem cells. Cancer Cell 11(1):69–82
Beck B, Driessens G, Goossens S et al (2011) A vascular niche and a VEGF-Nrp1 loop regulate the initiation and stemness of skin tumours. Nature 478(7369):399–403
Shen R, Ye Y, Chen L et al (2008) Precancerous stem cells can serve as tumor vasculogenic progenitors. PloS One 3(2):e1652
Wang R, Chadalavada K, Wilshire J et al (2010) Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468(7325):829–833
Sneddon JB, Werb Z (2007) Location, location, location: the cancer stem cell niche. Cell Stem Cell 1(6):607–611
Bao S, Wu Q, Sathornsumetee S et al (2006) Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66(16):7843–7848
Al-Hajj M, Wicha MS, Benito-Hernandez A et al (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7):3983–3988
Gong JF, Yuan YH, Song GH et al (2008) Pilot study on the correlation between high incidence of CD44+/CD24−/low/ABCG2-cells and poor prognosis in breast cancer. Beijing Da Xue Xue Bao 40(5):465–470
Abraham BK, Fritz P, McClellan M et al (2005) Prevalence of CD44+/CD24−/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 11(3):1154–1159
Liu R, Wang X, Chen GY et al (2007) The prognostic role of a gene signature from tumorigenic breast-cancer cells. New Engl J Med 356(3):217–226
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25(4):402–408
Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nature Rev 5(4):275–284
Okabe M, Tsukahara Y, Tanaka M et al (2009) Potential hepatic stem cells reside in EpCAM+ cells of normal and injured mouse liver. Development 136(11):1951–1960
Ginestier C, Hur MH, Charafe-Jauffret E et al (2007) ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 1(5):555–567
Croker AK, Goodale D, Chu J et al (2009) High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. J Cell Mol Med 13(8B):2236–2252
Charafe-Jauffret E, Ginestier C, Monville F et al (2006) Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene 25(15):2273–2284
Sorlie T, Perou CM, Tibshirani R et al (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–10874
Ailles LE, Weissman IL (2007) Cancer stem cells in solid tumors. Curr Opin Biotechnol 18(5):460–466
Ponti D, Costa A, Zaffaroni N et al (2005) Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65(13):5506–5511
Zhang Y, Toy KA, Kleer CG (2012) Metaplastic breast carcinomas are enriched in markers of tumor-initiating cells and epithelial to mesenchymal transition. Mod Pathol 25(2):178–184
Ratajczak M, Tarnowski M, Staniszewska M et al (2010) Mechanisms of cancer metastasis: involvement of cancer stem cells? Minerva Med 101(3):179–191
Arima Y, Hayashi N, Hayashi H et al (2012) Loss of p16 expression is associated with the stem cell characteristics of surface markers and therapeutic resistance in estrogen receptor-negative breast cancer. Int J Cancer 130(11):2568–2579
Idowu MO, Kmieciak M, Dumur C et al (2012) CD44(+)/CD24(−/low) cancer stem/progenitor cells are more abundant in triple-negative invasive breast carcinoma phenotype and are associated with poor outcome. Hum Pathol 43(3):364–373
Sheridan C, Kishimoto H, Fuchs RK et al (2006) CD44+/CD24− breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 8(5):R59
Saarinen NM, Abrahamsson A, Dabrosin C (2010) Estrogen-induced angiogenic factors derived from stromal and cancer cells are differently regulated by enterolactone and genistein in human breast cancer in vivo. Int J Cancer 127(3):737–745
Joyce JA, Pollard JW (2009) Microenvironmental regulation of metastasis. Nat Rev 9(4):239–252
Ambasta RK, Sharma A, Kumar P (2011) Nanoparticle mediated targeting of VEGFR and cancer stem cells for cancer therapy. Vasc Cell 3(1):26
Liekens S, Schols D, Hatse S (2011) CXCL12-CXCR4 axis in angiogenesis, metastasis and stem cell mobilization. Curr Pharm Des 16(35):3903–3920
Ehtesham M, Mapara KY, Stevenson CB et al (2009) CXCR4 mediates the proliferation of glioblastoma progenitor cells. Cancer Lett 274(2):305–312
Sakariassen PO, Prestegarden L, Wang J et al (2006) Angiogenesis-independent tumor growth mediated by stem-like cancer cells. Proc Natl Acad Sci USA 103(44):16466–16471
Jeyapalan Z, Deng Z, Shatseva T et al (2011) Expression of CD44 3′-untranslated region regulates endogenous microRNA functions in tumorigenesis and angiogenesis. Nucleic Acids Res 39(8):3026–3041
Bretz N, Noske A, Keller S et al (2011) CD24 promotes tumor cell invasion by suppressing tissue factor pathway inhibitor-2 (TFPI-2) in a c-Src-dependent fashion. Clin Exp Metastasis 29(1):27–38
Schabath H, Runz S, Joumaa S et al (2006) CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci 119(Pt 2):314–325
Kerbel RS (2008) Tumor angiogenesis. New Engl J Med 358(19):2039–2049
Kim KJ, Li B, Winer J et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362(6423):841–844
Relf M, LeJeune S, Scott PA et al (1997) Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 57(5):963–969
Hanrahan V, Currie MJ, Gunningham SP et al (2003) The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J Pathol 200(2):183–194
Viacava P, Naccarato AG, Bocci G et al (2004) Angiogenesis and VEGF expression in pre-invasive lesions of the human breast. J Pathol 204(2):140–146
Bergers G, Javaherian K, Lo KM et al (1999) Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284(5415):808–812
Hamilton EP, Blackwell KL (2011) Safety of bevacizumab in patients with metastatic breast cancer. Oncology 80(5–6):314–325
Besancon R, Valsesia-Wittmann S, Puisieux A et al (2009) Cancer stem cells: the emerging challenge of drug targeting. Curr Med Chem 16(4):394–416
Acknowledgments
We thank Dr. Hongxia Li (Department of Medical Oncology, Beijing Youan Hospital, Capital Medical University, Beijing, China) for constructive advices on the manuscript. This work was supported by Beijing Medical Oncology Leadership grant 2009-2-16 from Beijing Municipal Government Health Bureau.
Conflict of interest
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sun, H., Jia, J., Wang, X. et al. CD44+/CD24− breast cancer cells isolated from MCF-7 cultures exhibit enhanced angiogenic properties. Clin Transl Oncol 15, 46–54 (2013). https://doi.org/10.1007/s12094-012-0891-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-012-0891-2